Pioglitazone in Skin Fibrosis: Mechanistic Rationale and Therapeutic Potential of Pioglitazone for Scarring Dermatoses

Summary

This paper examines current literature surrounding the use of peroxisome proliferator-activated receptor γ (PPAR-γ) agonists in the treatment of cutaneous fibrosis. The rationale for repurposing pioglitazone is discussed, with a focus on the drug's dual anti-inflammatory and anti-fibrotic mechanisms. The literature on this topic encourages further clinical studies in this area.

Abstract

Cutaneous fibrosis – encompassing keloids, hypertrophic scars, localized scleroderma (morphea), and scarring alopecias – remains fundamentally undertreated, with conventional interventions frequently yielding incomplete therapeutic responses and high rates of recurrence. Pioglitazone, a Food and Drug Administration (FDA)-approved peroxisome proliferator-activated receptor γ (PPAR-γ) agonist traditionally utilized for glycemic control in type 2 diabetes mellitus, represents a highly compelling candidate for dermatologic repurposing. Beyond its canonical metabolic functions, robust target engagement of PPAR-γ by pioglitazone suppresses NF-κB–driven cytokine cascades, directly inhibits NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome assembly, promotes macrophage polarization toward tissue-reparative phenotypes, and disrupts profibrotic TGF-β/SMAD signaling architectures. Consequently, the drug exerts a dual mechanism of action, simultaneously attenuating chronic inflammation while inhibiting pathological fibrogenesis. This review expands upon prior analyses by integrating recently published clinical and scientific data, specifically highlighting new translational milestones, including human registry data in progeroid syndromes and randomized controlled trials in cicatricial alopecia. A distinct focus is placed on advancements in localized delivery strategies, such as nanostructured lipid carriers and niosomes, that offer the potential to overcome pioglitazone's inherent physicochemical constraints and thereby maximize dermal target engagement while avoiding systemic toxicities like heart failure and bladder cancer. Furthermore, this analysis synthesizes recent molecular insights connecting fibrosis and inflammation via target engagement biomarkers (e.g., FABP4, CD36) and proposes actionable, biomarker-driven trial designs, including adaptive basket trials, to bridge current gaps in dermatology-specific translation. Demonstrating localized anti-fibrotic and anti-inflammatory efficacy with minimal systemic risk could establish pioglitazone as a mechanism-based, disease-modifying therapy for a broad spectrum of fibrotic and scarring dermatologic disorders.

Introduction

Cutaneous fibrosis represents a complex, heterogeneous spectrum of dermatologic disorders in which aberrant, sustained wound healing responses lead to the excessive deposition of Extracellular Matrix (ECM) proteins, profound architectural distortion, and functional impairment. Conditions such as keloids, hypertrophic scars, and localized scleroderma (morphea), alongside chronic inflammatory dermatoses like Hidradenitis Suppurativa (HS) and primary scarring alopecias, currently lack consistently reliable, disease-modifying, and target-specific therapies¹. Conventional therapeutic options for keloids and hypertrophic scars – ranging from in....